Organon & Co.

OGNNYSEUSD
13.36 USD
0.04 (0.30%)AT CLOSE (11:59 AM EDT)
13.35
0.01 (0.04%)
POST MARKET (AS OF 08:15 PM EDT)
Post Market
AS OF 08:15 PM EDT
13.35
0.01 (0.04%)
🔴Market: CLOSED
Open?$13.38
High?$13.40
Low?$13.36
Prev. Close?$13.40
Volume?2.2M
Avg. Volume?11.5M
VWAP?$13.39
Rel. Volume?0.19x
Bid / Ask
Bid?$13.12 × 100
Ask?$13.40 × 2.0K
Spread?$0.28
Midpoint?$13.26
Valuation & Ratios
Market Cap?3.5B
Shares Out?262.6M
Float?261.5M
Float %?99.6%
P/E Ratio?14.26
P/B Ratio?3.89
EPS?$0.94
Dividend?0.63%
Ex-Dividend?N/A

Organon & Co. (OGN) trades at $13.36 per share. The technical outlook is "Buy" and the fundamental picture shows "Neutral". Notable factors include a concerning Altman Z-Score in the distress zone, exceptional Return on Equity (27.2%), a bullish Golden Cross on the moving averages and bullish moving average alignment. The stock looks compelling on valuation, with multiples below sector averages across P/E, P/B, and EV/EBITDA.

Technical & fundamental data as of Jun 5, 2026.

News
Profile
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
Employees
10.0K
Market Cap
3.5B
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2021-05-14
Address
30 HUDSON STREET
JERSEY CITY, NJ 07302
Phone: 551-430-6000
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)? Bullish(+1/3)
Medium-Term (Wave)? Neutral(0/3)
Short-Term (Ripple)? Neutral(0/3)
MA Alignment?Golden Alignment
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
60
Z-Score?
15
Momentum?
65
Short Sent.?
60
Piotroski F-Score?5/9Mixed
Altman Z-Score?1.22Distress
Confidence?67%Moderate
Full Fundamental Analysis →
Short InterestElevated
Short % of Float?7.66%Elevated
Short Interest?20.0M
Days to Cover?3.2
Free Float261.5M
Avg Daily Volume6.3M
Settlement Date2026-05-15
Financial Health
Current Ratio?1.97Adequate
Quick Ratio?1.42Adequate
Cash Ratio?0.45Low
Debt/Equity?9.49High
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
94/100
P/E?
Peers
100
S&P
83
14.3CHEAP
P/B?
Peers
100
S&P
45
3.89FAIR
P/S?
Peers
100
S&P
94
0.57CHEAP
P/FCF?
Peers
100
S&P
97
5.1CHEAP
EV/EBITDA?
Peers
100
S&P
93
7.2CHEAP
EV/Sales?
Peers
100
S&P
79
1.78CHEAP
Returns & Efficiency
ROE?
Peers
50
S&P
76
27.2%STRONG
ROA?
Peers
50
S&P
19
1.9%WEAK
Cash Flow & Enterprise
FCF?$683.0M
Enterprise Value?$11.0B
Fundamentals ratios updated end of day